<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066022</url>
  </required_header>
  <id_info>
    <org_study_id>CT0590-CG6012</org_study_id>
    <nct_id>NCT05066022</nct_id>
  </id_info>
  <brief_title>A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
  <official_title>Open Label, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of CT0590 Chimeric Antigen Receptor T Cell （CAR T）in Patients With Relapsed and/or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CARsgen Therapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single arm study to evaluate the safety and tolerability of treatment&#xD;
      with CT0590 CAR T in patients with relapsed and/or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 28, 2021</start_date>
  <completion_date type="Anticipated">July 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>CAR T</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of dose-limiting toxicity</measure>
    <time_frame>28 days post administration of CAR-T-cells</time_frame>
    <description>The incidence of dose-limiting toxicity（predetermined in protocol）and explore the appropriate dose</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Relapsed and/or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Experimental: CT0590 CAR T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-escalated CAR T cells infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT0590 CAR T Cells</intervention_name>
    <description>Dose-escalated CAR T cells infusion</description>
    <arm_group_label>Experimental: CT0590 CAR T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients and legally acceptable representative must have voluntarily signed Informed&#xD;
             Consent Form and willing to complete the study procedure, after fully understanding of&#xD;
             the study.&#xD;
&#xD;
          2. Age ≥ 18 years and ≤ 70 years, male or female.&#xD;
&#xD;
          3. The patients have received at least 3 prior regimen for multiple myeloma.&#xD;
&#xD;
          4. Subjects should have received treatment with at least one proteasome inhibitor and one&#xD;
             immunomodulatory drug (IMiD; and have been stable disease, relapsed or progressed&#xD;
             after treatment with at least one regimen consisting of above-mentioned medications.&#xD;
&#xD;
          5. Subjects should have relapsed within 12 months after the last line of therapy, or not&#xD;
             achieved at least minimal response (MR) or disease has progressed within 60 days after&#xD;
             last line of therapy (IMWG criteria 2016), with documented evidence.&#xD;
&#xD;
          6. Subjects should have measurable disease per IMWG 2016 criteria.&#xD;
&#xD;
          7. Expected survival &gt; 12 weeks.&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) scores 0 - 1.&#xD;
&#xD;
          9. Subjects should have adequate hemostatic and liver and kidney meet the following&#xD;
             examination criteria: (without ongoing supportive treatments):&#xD;
&#xD;
        1) Complete blood count (CBC) results: absolute neutrophil count（ANC） ≥ 1.0 × 109/L,&#xD;
        platelet count ≥ 75 × 109/L (if the proportion of plasma cells in the bone marrow is &gt; 50%,&#xD;
        subjects with platelets ≥ 50 × 109/L will be eligible), Hb ≥ 70 g/L.&#xD;
&#xD;
        2) Blood biochemistry: creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula), alanine&#xD;
        aminotransferase (ALT) ≤ 2.5 × upper limit normal (ULN)，aspartate aminotransferase (AST) ≤&#xD;
        2.5 × ULN, total bilirubin ≤ 2 × ULN.&#xD;
&#xD;
        10. Women of childbearing age must undergo a serum pregnancy test with negative results at&#xD;
        screening and before lymphodepletion and be willing to use an effective and reliable method&#xD;
        of contraception for at least 1 year after T cell infusion. All female subjects are&#xD;
        prohibited from egg donation within 1 year after T cell infusion.&#xD;
&#xD;
        11. Men must be willing to use an effective and reliable method of contraception for at&#xD;
        least 1 year after T cell infusion if they have sexual activity with women of childbearing&#xD;
        potential. All male subjects are prohibited from sperm donation within 1 year after T cell&#xD;
        infusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women.&#xD;
&#xD;
          2. Subjects positive for any following tests: human immunodeficiency virus (HIV)&#xD;
             antibody, Treponema pallidum (syphilis) antibody, hepatitis C virus (HCV) antibody,&#xD;
             hepatitis B virus (HBV) surface antigen (HBsAg) and HBV DNA.&#xD;
&#xD;
          3. Subjcets with any uncontrolled active infection, including but not limited to active&#xD;
             tuberculosis (TB) (judged by investigator).&#xD;
&#xD;
          4. Subjects with AEs from previous treatment that have not recovered to Common&#xD;
             Terminology Criteria for Adverse Events (CTCAE) v5.0 ≤ 1, excluding hair loss and&#xD;
             other events that the treating physician considers as tolerable.&#xD;
&#xD;
          5. Subjects who have received CAR T therapy for any targets.&#xD;
&#xD;
          6. Subjects who have had anti-B Cell Maturation Antigen（BCMA） therapy.&#xD;
&#xD;
          7. Subjects who have received allogeneic stem cell transplantation for multiple myeloma.&#xD;
&#xD;
          8. Subjects who have received autologous stem cell transplantation less than 12 weeks&#xD;
             before leukapheresis.&#xD;
&#xD;
          9. Subjects who have received any anti-myeloma treatment 14 days before leukapheresis,&#xD;
             including but not limited to cytotoxic therapy, proteasome inhibitor, immunomodulator,&#xD;
             target therapy, monoclonal antibodies, radiotherapy, epigenetic therapy or&#xD;
             investigational drug, or the use of invasive investigational medical device. If the&#xD;
             field of radiation covers ≤ 5% of the bone marrow, the subjects are eligible to&#xD;
             participate in the study regardless of the radiotherapy end date.&#xD;
&#xD;
         10. Subjects who have received ≥ 15 mg prednisone daily or other equivalent dose of&#xD;
             steroids within 7 days before leukapheresis, except inhaled steroids.&#xD;
&#xD;
         11. Subjects who have plasma cell leukemia, Waldenström macroglobulinemia, POEMS syndrome&#xD;
             or primary light chain amyloidosis.&#xD;
&#xD;
         12. Subjects who have been received a live attenuated vaccine 4 weeks before&#xD;
             leukapheresis.&#xD;
&#xD;
         13. Subjects allergic to or intolerant of fludarabine, cyclophosphamide, tocilizumab, or&#xD;
             allergic to the ingredients (DMSO) of CT0590 T cell preparations; subject with&#xD;
             confirmed another serious allergy history.&#xD;
&#xD;
         14. Subjects who have any of the following conditions within 6 months prior to the signing&#xD;
             of inform consent: uncontrolled congestive heart failure (New York Heart Association&#xD;
             (NYHA) stage III or IV), angina, myocardial infarction, stroke (except lacunar&#xD;
             infarct), coronary artery bypass graft, clinically meaningful (judged by investigator)&#xD;
             arrhythmia (including but not limited to ventricular arrhythmia, significant QT&#xD;
             interval prolongation (Bazett's formula corrected QT,corrected QT ≥ 500 ms, judged by&#xD;
             investigator), uncontrolled blood pressure as defined as systolic &gt; 160 mmHg,&#xD;
             diastolic &gt;100 mmHg, uncontrolled diabetes as defined as HbA1c &gt;8% after treatment,&#xD;
             pulmonary embolism, or other conditions that the investigator believe that&#xD;
             participating in this clinical trial may endanger the health of the subjects.&#xD;
&#xD;
         15. Blood oxygen saturation that can only be maintained at &gt; 95% by oxygen inhalation&#xD;
             before leukapheresis.&#xD;
&#xD;
         16. Subjects known to have active autoimmune diseases including but not limited to&#xD;
             psoriasis, rheumatoid arthritis and other conditions that require long-term&#xD;
             immunosuppressive therapy.&#xD;
&#xD;
         17. Subjects with second malignancies in addition to multiple myeloma are not eligible if&#xD;
             the second malignancy has required treatment within the past 5 years, with the&#xD;
             exception of low grade malignancies.&#xD;
&#xD;
         18. Subjects who have central nervous system (CNS) metastases or symptomatic CNS&#xD;
             involvement.&#xD;
&#xD;
         19. Subjects who are unable or unwilling to comply with the requirements of clinical trial&#xD;
             or other reasons that are not suitable for participating in the clinical trial.&#xD;
&#xD;
         20. Subjects who have received major surgery 2 weeks prior to leukapheresis or plan to&#xD;
             receive major surgery within 4 weeks after cell infusion (excluding cataract and other&#xD;
             local anesthesia).&#xD;
&#xD;
         21. Subjects who are related to investigator or study personnel, or with possible conflict&#xD;
             of interest with the investigator or study personnel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chengcheng Fu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>World Health Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>chengcheng Fu, PhD</last_name>
    <phone>0512-67781856</phone>
    <email>fuzhengzheng@suda.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>chengcheng Fu, PhD</last_name>
      <phone>0512-67781856</phone>
      <email>fuzhengzheng@suda.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Soochow University</investigator_affiliation>
    <investigator_full_name>Fu chengcheng PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

